LintonPharm Co., Ltd. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of becoming the worldwide leader in CD3 bispecific antibody. LintonPharm, in collaboration with Lindis Biotech, is developing Catumaxomab for use in a broad range of cancers globally.

We have an industry-leading management team and scientific advisors with rich experience in cancer immunotherapy especially T cell engagers, and with antibody engineering, advancing drug candidates from early-stage research to clinical trials and regulatory approval.

Guided by our core value – leading immunotheraqpy with unique CD3 platform, we relentlessly build on our expertise in cancer immunology and leading-edge technologies in pursuit of transformative treatments for cancer patients. We approach each day with our commitment and passion to improve lives of patients, and a sense of humility, recognizing that our strength resides in the diversity of our journeys and the opportunity to learn from each other.